Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
19.19
USD
-0.01 (-0.05%)
Official Closing Price
Updated: 6:47 PM EST, Mar 2, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Alkermes Announces 3rd Annual ALKERMES PATHWAYS RESEARCH AWARDS℠ Program and 2019 Recipients
June 29, 2020
Tags
Public Health
CNS disorders
Improving Healthcare Access
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
June 29, 2020
-- The Competitive Grant Program Offers Individual Grant Amounts of Up To $100,000 per Project --
From
PR Newswire
Men's Health Month and Melanoma
June 26, 2020
Tags
Health & Healthcare
Disease Awareness
Diversity & Inclusion
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Pride Month Celebration at Alkermes
June 25, 2020
Tags
COVID/19
Responsible Business & Employee Engagement
Diversity & Inclusion
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
June 24, 2020
Tags
Corporate Contributions
Public Health
Improving Healthcare Access
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
June 24, 2020
- Special Edition of Alkermes Inspiration Grants® Program Focused on Addressing Pandemic-Related Needs of People Living with Addiction, Serious Mental Illness, or Cancer -
From
PR Newswire
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
June 22, 2020
- Combination Therapy Resulted in Durable, Dose-Dependent Antitumor Efficacy in a Preclinical Model of Colon Cancer -
From
PR Newswire
Alkermes: Our Responsibility to Combat Discrimination and Racism
June 19, 2020
Tags
Responsible Business & Employee Engagement
Employee Resource Group
Reduced Inequalities
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
June 04, 2020
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 at 9:40 a.m. ET...
From
PR Newswire
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 27, 2020
-- Findings From Qualitative Patient Substudy Evaluating Health-Related Quality of Life in Patients With Schizophrenia and Treatment Satisfaction, Including Treatment with ALKS 3831, to be Presented...
From
PR Newswire
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 20, 2020
-- Phase 3b Study Evaluated Efficacy and Safety of ARISTADA® 2-month Dose, Together With ARISTADA INITIO® One-day Initiation Regimen, in Patients Hospitalized for Acute Schizophrenia --
From
PR Newswire
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
May 14, 2020
-- E-Poster Presentations Include Results From Completed 52-Week, Open-Label Safety Study of ALKS 3831 in Patients With Schizophrenia --
From
PR Newswire
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
May 11, 2020
-- Retail Pharmacies, Including 900 Albertsons Locations, Added to the Provider Locator to Provide Injections of ARISTADA and VIVITROL; Additional Programs In Place to Deliver Support and Financial...
From
PR Newswire
Collaborative and Risk-focused Engagement (CaRE™) at Alkermes
May 07, 2020
Tags
Alkermes
safety
Workplace Safety
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
May 06, 2020
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 2020 Bank of America Securities Virtual Health Care Conference on Wednesday, May 13, 2020 at 9:40...
From
PR Newswire
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
May 04, 2020
- Special Edition of Alkermes Inspiration Grants® Program Designed to Support COVID-19-Related Needs of People Affected by Addiction, Serious Mental Illness or Cancer -
From
PR Newswire
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
May 04, 2020
Tags
Improving Healthcare Access
Alkermes
Disaster Relief
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Statement from Alkermes on Response to COVID-19
May 01, 2020
Tags
Safety
Mental Health
Disease Awareness
From
3BL Media: Corporate Social Responsibility, Energy and Health News
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
April 29, 2020
-- First Quarter Revenues of $246.2 Million, Primarily Driven by 30% Year-Over-Year Growth of Proprietary Product Net Sales --
From
PR Newswire
Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
April 22, 2020
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to discuss the company's first quarter 2020 financial...
From
PR Newswire
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
April 22, 2020
- In Preclinical Model, ALKS 4230 Exhibited Improved Anti-tumor Efficacy and Lower Toxicity Relative to Recombinant Human IL-2 -
From
PR Newswire
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
March 04, 2020
Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, Journal of...
From
PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
February 24, 2020
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30...
From
PR Newswire
Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 19, 2020
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26, 2020 at 9:00 a.m. ET (2:00 p.m....
From
PR Newswire
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
February 13, 2020
-- Revenues of $1.17 Billion in 2019, Driven by Year-Over-Year Growth of Proprietary Product Net Sales and VUMERITY® Milestone Payment --
From
PR Newswire
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
February 06, 2020
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company's fourth quarter and year-end 2019...
From
PR Newswire
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
January 28, 2020
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831...
From
PR Newswire
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00...
From
PR Newswire
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 26, 2019
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3,...
From
PR Newswire
Alkermes Completes Acquisition of Rodin Therapeutics
November 25, 2019
-- Acquisition Expands Alkermes' Research and Development Efforts to Include Small Molecule Therapeutics for Synaptopathies --
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.